See Appendix S1 for study group.
A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection
Article first published online: 3 OCT 2013
© 2013 British HIV Association
Volume 15, Issue 3, pages 144–152, March 2014
How to Cite
Mocroft, A., Ryom, L., Reiss, P., Furrer, H., D'Arminio Monforte, A., Gatell, J., de Wit, S., Beniowski, M., Lundgren, J., Kirk, O. and for EuroSIDA in EuroCOORD (2014), A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection. HIV Medicine, 15: 144–152. doi: 10.1111/hiv.12095
- Issue published online: 4 FEB 2014
- Article first published online: 3 OCT 2013
- Manuscript Accepted: 26 AUG 2013
- European Commission. Grant Numbers: CT94-1637, CT97-2713
- 5th Framework. Grant Number: QLK2-2000-00773
- 6th Framework. Grant Number: LSHP-CT-2006-018632
- 7th Framework. Grant Numbers: FP7/2007-2013, EuroCoord n° 260 694
- Janssen R&D
- Merck and Co. Inc.
- Pfizer Inc.
- GlaxoSmithKline LLC
- The Swiss National Science Foundation. Grant Number: 108787
- chronic kidney disease;
- end stage renal disease;
- renal function
The aim of this study was to determine whether the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)- or Cockcroft−Gault (CG)-based estimated glomerular filtration rates (eGFRs) performs better in the cohort setting for predicting moderate/advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD).
A total of 9521 persons in the EuroSIDA study contributed 133 873 eGFRs. Poisson regression was used to model the incidence of moderate and advanced CKD (confirmed eGFR < 60 and < 30 mL/min/1.73 m2, respectively) or ESRD (fatal/nonfatal) using CG and CKD-EPI eGFRs.
Of 133 873 eGFR values, the ratio of CG to CKD-EPI was ≥ 1.1 in 22 092 (16.5%) and the difference between them (CG minus CKD-EPI) was ≥ 10 mL/min/1.73 m2 in 20 867 (15.6%). Differences between CKD-EPI and CG were much greater when CG was not standardized for body surface area (BSA). A total of 403 persons developed moderate CKD using CG [incidence 8.9/1000 person-years of follow-up (PYFU); 95% confidence interval (CI) 8.0–9.8] and 364 using CKD-EPI (incidence 7.3/1000 PYFU; 95% CI 6.5–8.0). CG-derived eGFRs were equal to CKD-EPI-derived eGFRs at predicting ESRD (n = 36) and death (n = 565), as measured by the Akaike information criterion. CG-based moderate and advanced CKDs were associated with ESRD [adjusted incidence rate ratio (aIRR) 7.17; 95% CI 2.65–19.36 and aIRR 23.46; 95% CI 8.54–64.48, respectively], as were CKD-EPI-based moderate and advanced CKDs (aIRR 12.41; 95% CI 4.74–32.51 and aIRR 12.44; 95% CI 4.83–32.03, respectively).
Differences between eGFRs using CG adjusted for BSA or CKD-EPI were modest. In the absence of a gold standard, the two formulae predicted clinical outcomes with equal precision and can be used to estimate GFR in HIV-positive persons.